Details
Stereochemistry | RACEMIC |
Molecular Formula | C32H39NO4.ClH |
Molecular Weight | 538.117 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN2CCC(CC2)C(O)(C3=CC=CC=C3)C4=CC=CC=C4
InChI
InChIKey=RRJFVPUCXDGFJB-UHFFFAOYSA-N
InChI=1S/C32H39NO4.ClH/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27;/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36);1H
DescriptionCurator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00950
Curator's Comment: Description was created based on several sources, including https://www.drugbank.ca/drugs/DB00950
Fexofenadine is a second-generation, long lasting H1-receptor antagonist (antihistamine) which has a selective and peripheral H1-antagonist action. Histamine is a chemical that causes many of the signs that are part of allergic reactions, such as the swelling of tissues. Histamine is released from histamine-storing cells (mast cells) and attaches to other cells that have receptors for histamine. The attachment of the histamine to the receptors causes the cell to be "activated," releasing other chemicals which produce the effects that we associate with allergy. Fexofenadine blocks one type of receptor for histamine (the H1 receptor) and thus prevents activation of cells by histamine. Unlike most other antihistamines, Fexofenadine does not enter the brain from the blood and, therefore, does not cause drowsiness. Fexofenadine lacks the cardiotoxic potential of terfenadine, since it does not block the potassium channel involved in repolarization of cardiac cells. Fexofenadine is sold under the trade name Allegra among others. ALLEGRA is indicated for the relief of symptoms associated with seasonal allergic
rhinitis in adults and children 2 years of age and older.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
246.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ALLEGRA Approved UseALLEGRA is indicated for the relief of symptoms associated with seasonal allergic
rhinitis in adults and children 2 years of age and older. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
523.28 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27151911 |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FEXOFENADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3507.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27151911 |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FEXOFENADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.26 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27151911 |
120 mg single, oral dose: 120 mg route of administration: Oral experiment type: SINGLE co-administered: |
FEXOFENADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Other AEs: Headache, Tiredness... Other AEs: Headache (3 patients) Sources: Tiredness (3 patients) Dizziness (3 patients) |
800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Other AEs: Headache, Tiredness... Other AEs: Headache (3 patients) Sources: Tiredness (3 patients) Dizziness (3 patients) |
60 mg 2 times / day multiple, oral Highest studied dose Dose: 60 mg, 2 times / day Route: oral Route: multiple Dose: 60 mg, 2 times / day Sources: |
unhealthy, 6-11 years Health Status: unhealthy Condition: seasonal allergic rhinitis Age Group: 6-11 years Sex: M+F Sources: |
|
180 mg 1 times / day multiple, oral Dose: 180 mg, 1 times / day Route: oral Route: multiple Dose: 180 mg, 1 times / day Sources: |
unhealthy, 69 years n = 1 Health Status: unhealthy Age Group: 69 years Sex: M Population Size: 1 Sources: |
Disc. AE: Papular urticarial eruption... AEs leading to discontinuation/dose reduction: Papular urticarial eruption (1 patient) Sources: |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p. 22 |
unhealthy Health Status: unhealthy Sources: Page: p. 22 |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (2 patients) Sources: Page: p. 22 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 3 patients | 690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Headache | 3 patients | 690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Tiredness | 3 patients | 690 mg 2 times / day multiple, oral Highest studied dose Dose: 690 mg, 2 times / day Route: oral Route: multiple Dose: 690 mg, 2 times / day Sources: |
healthy, 18-55 years n = 4 Health Status: healthy Age Group: 18-55 years Sex: M Population Size: 4 Sources: |
Dizziness | 3 patients | 800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Headache | 3 patients | 800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Tiredness | 3 patients | 800 mg single, oral Highest studied dose |
healthy, 26.9 years (range: 18-51) years n = 8 Health Status: healthy Age Group: 26.9 years (range: 18-51) years Sex: M Population Size: 8 Sources: |
Papular urticarial eruption | 1 patient Disc. AE |
180 mg 1 times / day multiple, oral Dose: 180 mg, 1 times / day Route: oral Route: multiple Dose: 180 mg, 1 times / day Sources: |
unhealthy, 69 years n = 1 Health Status: unhealthy Age Group: 69 years Sex: M Population Size: 1 Sources: |
Headache | 2 patients Disc. AE |
30 mg 1 times / day multiple, oral Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: Page: p. 22 |
unhealthy Health Status: unhealthy Sources: Page: p. 22 |
PubMed
Title | Date | PubMed |
---|---|---|
Treatment of urticaria. An evidence-based evaluation of antihistamines. | 2001 |
|
Causality assessment of adverse effects: when is re-challenge ethically acceptable? | 2001 |
|
Fexofenadine reduces nasal congestion in perennial allergic rhinitis. | 2001 Nov |
|
The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis. | 2001 Oct |
|
Urticaria to cetirizine. | 2002 |
|
Liquid chromatography/tandem mass spectrometric bioanalysis using normal-phase columns with aqueous/organic mobile phases - a novel approach of eliminating evaporation and reconstitution steps in 96-well SPE. | 2002 |
|
Photosensitivity disorders: cause, effect and management. | 2002 |
|
Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. | 2002 |
|
[Hay fever and asthma. Many of your patients have both]. | 2002 Apr 25 |
|
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. | 2002 Aug 5 |
|
Sea transport of animal and vegetable oils and its environmental consequences. | 2002 Dec |
|
Effect of fexofenadine, a mast cell blocker, in infertile men with significantly increased testicular mast cells. | 2002 Dec |
|
Inhibitory effects of oral prednisolone and fexofenadine on skin responses by prick tests with histamine and compound 48/80. | 2002 Dec |
|
Comparative pharmacology of H1 antihistamines: clinical relevance. | 2002 Dec 16 |
|
Treatment of allergic rhinitis. | 2002 Dec 16 |
|
Role of histamine in the pathophysiology of asthma: immunomodulatory and anti-inflammatory activities of H1-receptor antagonists. | 2002 Dec 16 |
|
A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. | 2002 Feb |
|
An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. | 2002 Jan |
|
Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. | 2002 Jan |
|
Determination of fexofenadine in human plasma and urine by liquid chromatography-mass spectrometry. | 2002 Jan 25 |
|
In vivo anti-inflammatory effects of fexofenadine in chronic idiopathic urticaria. | 2002 Jul |
|
Onset of action, efficacy, and safety of fexofenadine 60 mg/pseudoephedrine 120 mg versus placebo in the Atlanta allergen exposure unit. | 2002 Jul |
|
Role of lung inflammatory mediators as a cause of exercise-induced arterial hypoxemia in young athletes. | 2002 Jul |
|
Chronic urticaria and angioedema. | 2002 Jul 18 |
|
Simultaneous determination of fexofenadine and its related compounds by HPLC. | 2002 Jul 20 |
|
Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. | 2002 Jun |
|
Effect of St John's wort on the pharmacokinetics of fexofenadine. | 2002 Jun |
|
Are herbal products dietary supplements or drugs? An important question for public safety. | 2002 Jun |
|
Evaluation of cytokines in nasal secretions after nasal antigen challenge: lack of influence of antihistamines. | 2002 May |
|
MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. | 2002 May |
|
Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. | 2002 May |
|
Clinical pharmacology of H1-antihistamines in the skin. | 2002 Nov |
|
The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia. | 2002 Nov |
|
Review of fexofenadine in the treatment of chronic idiopathic urticaria. | 2002 Oct |
|
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis. | 2002 Oct |
|
Determination of some histamine H1-receptor antagonists in dosage forms. | 2002 Oct 15 |
|
Chronic urticaria: a role for newer immunomodulatory drugs? | 2003 |
|
The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. | 2003 Apr |
|
Sedation and performance impairment of diphenhydramine and second-generation antihistamines: a meta-analysis. | 2003 Apr |
|
Fexofenadine is efficacious and safe in children (aged 6-11 years) with seasonal allergic rhinitis. | 2003 Apr |
|
The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. | 2003 Feb |
|
Failure of cetirizine and fexofenadine to prevent motion sickness. | 2003 Feb |
|
Effect of fexofenadine hydrochloride on cedar pollinosis. | 2003 Feb |
|
[Effect of fexofenadine--selective antagonist of histamine receptor (H1) on histamine-induced bronchoconstriction]. | 2003 Jan |
|
Internal standard signal suppression by co-eluting analyte in isotope dilution LC-ESI-MS. | 2003 Jan |
|
Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. | 2003 Jan |
|
Why aren't lower, effective, OTC doses available earlier by prescription? | 2003 Jan |
|
Solar urticaria induced by infrared radiation. | 2003 Mar |
|
Decongestant effects of antihistamines: a class effect? | 2003 Mar |
|
Spectrophotometric determination of binary mixtures of pseudoephedrine with some histamine H1-receptor antagonists using derivative ratio spectrum method. | 2003 Mar 26 |
Sample Use Guides
Seasonal Allergic Rhinitis and Chronic Idiopathic Urticaria
Adults and Children 12 Years and Older: The recommended dose of ALLEGRA (Fexofenadine)
tablets is 60 mg twice daily or 180 mg once daily with water. A dose of 60 mg once daily is
recommended as the starting dose in patients with decreased renal function
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24260772
The addition of fexofenadine at a dose of 10E-4 M elicited a significant relaxation response in isolated rat tracheas.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29578
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5048716
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
236474
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB13884MIG
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
153439-40-8
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
C29050
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
FF-73
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
1270377
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
100000092281
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
63002
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
m5367
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL914
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
DBSALT001227
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
2S068B75ZU
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY | |||
|
2S068B75ZU
Created by
admin on Fri Dec 15 16:49:24 GMT 2023 , Edited by admin on Fri Dec 15 16:49:24 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD